Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Simultaneous Fluorescence Immunophenotyping and Her-2/ neu

Simultaneous Fluorescence Immunophenotyping and Her-2/ neu TECHNICAL ARTICLE Simultaneous Fluorescence Immunophenotyping and Her-2/neu Genotyping (FICTION) in Breast Carcinoma Candidates to Target Therapy Luisa Benerini Gatta, PhD, Paolo Incardona, MD, Moris Cadei, ThS, Piergiovanni Grigolato, MD, Sabrina Simoncelli, ThS, and Piera Balzarini, PhD olecular-targeted therapy using trastuzumab (Her- Abstract: The study of proto-oncogene Her-2/neu using the Mceptin, F. Hoffmann-La Roche, Basel, Switzer- fluorescence in situ hybridization (FISH) technique in routinely land), a humanized monoclonal antibody against human paraffin-embedded formalin-fixed tissue has become common- epidermal growth factor receptor type-2 (ERBB-2), gen- place over the past decade and mandatory among invasive erally referred to as “Her-2/neu,” is considered to be ef- breast cancer expressing a score 2+ by immunohistochemical fective for metastatic as well as primary breast cancer and analysis of c-erbB2 protein. The patient’s eligibility for treat- has already become a worldwide standard therapy for ment with the biological drug trastuzumab/herceptin is based on patients with protein overexpression and gene amplifica- the evidence of a Her-2/neu proto-oncogene amplification (ratio tion, alone or as part of a chemotherapeutic or combined Her-2/neu/CEP-17>2.2). However, although the exclusion is treatment (http://www.herceptin.com). declared in the absence of Her-2/neu gene amplification (ratio The evaluation of Her-2/neu status is considered to Her-2/neu/CEP-17 <1.8) according http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Simultaneous Fluorescence Immunophenotyping and Her-2&sol; neu

Download PDF
8 pages

Loading next page...
 
/lp/wolters-kluwer-health/simultaneous-fluorescence-immunophenotyping-and-her-2-sol-neu-LgNnWHY4w5

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2012 by Lippincott Williams & Wilkins
ISSN
1541-2016
DOI
10.1097/PAI.0b013e31823fb322
pmid
22417857
Publisher site
See Article on Publisher Site

Abstract

TECHNICAL ARTICLE Simultaneous Fluorescence Immunophenotyping and Her-2/neu Genotyping (FICTION) in Breast Carcinoma Candidates to Target Therapy Luisa Benerini Gatta, PhD, Paolo Incardona, MD, Moris Cadei, ThS, Piergiovanni Grigolato, MD, Sabrina Simoncelli, ThS, and Piera Balzarini, PhD olecular-targeted therapy using trastuzumab (Her- Abstract: The study of proto-oncogene Her-2/neu using the Mceptin, F. Hoffmann-La Roche, Basel, Switzer- fluorescence in situ hybridization (FISH) technique in routinely land), a humanized monoclonal antibody against human paraffin-embedded formalin-fixed tissue has become common- epidermal growth factor receptor type-2 (ERBB-2), gen- place over the past decade and mandatory among invasive erally referred to as “Her-2/neu,” is considered to be ef- breast cancer expressing a score 2+ by immunohistochemical fective for metastatic as well as primary breast cancer and analysis of c-erbB2 protein. The patient’s eligibility for treat- has already become a worldwide standard therapy for ment with the biological drug trastuzumab/herceptin is based on patients with protein overexpression and gene amplifica- the evidence of a Her-2/neu proto-oncogene amplification (ratio tion, alone or as part of a chemotherapeutic or combined Her-2/neu/CEP-17>2.2). However, although the exclusion is treatment (http://www.herceptin.com). declared in the absence of Her-2/neu gene amplification (ratio The evaluation of Her-2/neu status is considered to Her-2/neu/CEP-17 <1.8) according

Journal

Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health

Published: Jul 1, 2012

There are no references for this article.